CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Dose hope for devastating brain cancer spread
Disease control OngoingThis early-stage trial is testing a new way to give an immunotherapy drug called nivolumab to patients with melanoma or lung cancer that has spread to the membranes surrounding the brain and spinal cord. The goal is to see if giving the drug directly into the spinal fluid, along …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Precision radiation zaps brain tumors, aims to spare memory
Disease control OngoingThis study is testing a highly focused, single-dose radiation treatment for people with melanoma that has spread to more than three spots in the brain. The main goals are to see if this treatment can control the brain tumors and, importantly, if it causes less memory and thinking…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
Cancer trial aims to crack the code on treatment sequence for deadly skin cancer
Disease control OngoingThis study is for people with advanced melanoma that has a specific BRAF gene mutation and cannot be removed by surgery. It is testing which order of two powerful treatment combinations leads to longer survival. One group starts with immunotherapy (ipilimumab + nivolumab) and swi…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists test Triple-Threat drug cocktail in fight against advanced skin cancer
Disease control OngoingThis study is testing a new three-drug combination to see if it works better than the current two-drug standard for treating advanced melanoma with a specific BRAF gene mutation. The trial aims to find the safest dose and see if adding a third drug (navitoclax) helps shrink tumor…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New strategy: shrink tumors before surgery to fight advanced melanoma
Disease control OngoingThis study is comparing two different timing strategies for an immunotherapy drug called pembrolizumab in patients with high-risk melanoma that can be surgically removed. It aims to see if giving the drug *before* surgery (to shrink the tumor) works better than the standard appro…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists test new drug duo to fight tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Balancing act: fighting cancer while protecting a transplanted kidney
Disease control OngoingThis early-phase study is testing a combination of immunotherapy drugs (nivolumab and ipilimumab) along with standard transplant medications (tacrolimus and prednisone) in kidney transplant patients with advanced skin cancers that have spread or cannot be removed by surgery. The …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Major cancer trial tests new drug to stop deadly Melanoma's return
Disease control OngoingThis large, late-stage trial is testing if a drug called pembrolizumab works better than current standard treatments to prevent melanoma skin cancer from coming back or spreading after surgery. It enrolled over 1,300 patients with high-risk stage III or IV melanoma whose tumors w…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for Tough-to-Treat skin cancer: trial tests Triple-Drug attack
Disease control OngoingThis study is testing a new three-drug combination for people with advanced melanoma that has a specific genetic change (BRAF mutation) and has gotten worse despite standard targeted therapy. The goal is to see if adding a drug called tazemetostat to two existing drugs (dabrafeni…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New combo attack on deadly melanoma brain tumors
Disease control OngoingThis study is testing whether combining the drugs Avastin and Tencentriq, with or without a third drug called Cotellic, can help control melanoma that has spread to the brain. It is for adults with this specific type of advanced skin cancer who have not yet received treatment for…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists test new Cancer-Fighting duo in early trial
Disease control OngoingThis early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Can your diet boost cancer treatment? new study investigates
Disease control OngoingThis study is testing whether eating a high-fiber diet can improve gut health and help the immune system fight cancer in patients with advanced melanoma who are receiving standard immunotherapy. Fifty participants will be randomly assigned to follow either a high-fiber diet or a …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Trial aims to cut cancer treatment time in half using scans
Disease control OngoingThis study is testing if doctors can safely stop a standard immunotherapy treatment early for people with advanced melanoma. It uses special PET scans and sometimes a biopsy taken after one year of treatment to check if the cancer is under control. If the scan and biopsy show no …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC